

**AMENDMENTS TO THE CLAIMS**

Listing of Claims

1-22. (Canceled).

23. (Currently Amended) A method for treating Alzheimer's disease, mild cognitive impairment or cerebral amyloid angiopathy, which comprises administering to a mammal an effective dose of a monoclonal antibody, (a) wherein said antibody recognizes  $\beta$ -amyloid (1-42) having the amino acid sequence represented by SEQ ID NO: 5 and which specifically reacts with a partial peptide at the C-terminal region of a  $\beta$ -amyloid or a derivative thereof ~~and does not recognize a partial peptide having the amino acid sequence represented by SEQ ID NO: 8,~~ wherein the derivative is any of a peptide lacking 1 to 17 amino acid residue(s) in the N-terminal region of the  $\beta$ -amyloid, a peptide in which L-aspartic acid of the  $\beta$ -amyloid is isomerized to L-isoaspartic acid, D-isoaspartic acid or D-aspartic acid, a peptide having pyroglutamic acid in the N-terminal region of the  $\beta$ -amyloid, and a peptide having the amino acid sequence in which any of the 1st, the 1st to the 2nd, the 1st to the 3rd, the 1st to the 4th, the 1st to the 5th, the 1st to the 6th, the 1st to the 7th, the 1st to the 8th, the 1st to the 9th, and the 1st to the 10th amino acid(s) from the N-terminal region in the  $\beta$ -amyloid are lacking and the N-terminal glutamic acid is converted into pyroglutamic acid, and

(b) wherein said antibody does not recognize any of

- (i) a partial peptide having the amino acid sequence represented by SEQ ID NO: 8,
- (ii)  $\beta$ -amyloid (1-38) having the amino acid sequence represented by SEQ ID NO: 1,
- (iii)  $\beta$ -amyloid (1-39) having the amino acid sequence represented by SEQ ID NO: 2,
- and (iv)  $\beta$ -amyloid (1-40) having the amino acid sequence represented by SEQ ID NO: 3.

24. (Previously presented) The method according to claim 23, which is a method for treating Alzheimer's disease.

25-34. (Canceled).

35. (Previously presented) The method according to claim 23, wherein said antibody is monoclonal antibody BC-05a, which is producible from the hybridoma indicated by BC-05 (FERM BP-4457).

36.-42. (Canceled).

43. (Withdrawn) An agent for preventing and/or treating Alzheimer's disease, mild cognitive impairment or cerebral amyloid angiopathy, comprising a monoclonal antibody, which specifically reacts with a partial peptide at the C-terminal region of a  $\beta$ -amyloid or a derivative thereof and does not recognize a partial peptide having the amino acid sequence represented by SEQ ID NO: 8.